Between weeks 49 and 52, mepolizumab-treated participants exhibited significantly greater changes from baseline vs placebo-treated participants in their loss-of-smell VAS symptom scores (–3.00± ...

Table 5 shows the percentage of patients who scored in the negative half of the VAS symptom scales (scores <70). For most symptoms the highest percentage of problems was at T3.

The mean VAS NSS scores for rhinorrhea and nasal congestion significantly improved from baseline (both p<0.0001), achieving a mean percent change of 53% and 55%, respectively.

Shen F, Hu LH, Huang HS, Li L. Development and validation of the scale for symptom clusters in patients with myasthenia gravis. BMC Neurol. Published online May 19, ...

Separately, the Symptom Composite Score, based on seven Visual Analog Scale (VAS) symptom ratings, was used to quantify overall symptom burden from the patient's perspective.

In a previous study, we described the development and preliminary evaluation of a parent-reported symptom instrument for children with AOM. [6] In the present report, we present additional data on ...